Longitudinal Observation of Insulin Secretory Ability Before and After the Onset of Immune Checkpoint Inhibitor-induced Diabetes Mellitus: A Report of Two Cases

Overview

Journal Clin Case Rep

Date 2021 Sep 15

PMID 34522382

Citations 2

Authors

Noriko Fujiwara

Mayu Watanabe

Akihiro Katayama

Yohei Noda

Jun Eguchi

Hitomi Kataoka

Shunsuke Kagawa

Jun Wada

Affiliations

Soon will be listed here.

Abstract

Immune checkpoint inhibitor-induced diabetes mellitus is a rare immune-related adverse event. This report illustrates clinical data and insulin secretory ability before and after the onset of immune checkpoint inhibitor-induced diabetes.

Citing Articles

Flash Glucose Monitoring and Diabetes Mellitus Induced by Immune Checkpoint Inhibitors: An Approach to Clinical Practice.

Rodriguez de Vera-Gomez P, Pinar-Gutierrez A, Guerrero-Vazquez R, Bellido V, Morales-Portillo C, Sancho-Marquez M J Diabetes Res. 2022; 2022:4508633.

PMID: 36387939 PMC: 9652069. DOI: 10.1155/2022/4508633.

Longitudinal observation of insulin secretory ability before and after the onset of immune checkpoint inhibitor-induced diabetes mellitus: A report of two cases.

Fujiwara N, Watanabe M, Katayama A, Noda Y, Eguchi J, Kataoka H Clin Case Rep. 2021; 9(9):e04574.

PMID: 34522382 PMC: 8424178. DOI: 10.1002/ccr3.4574.

References

Brahmer J, Tykodi S, Chow L, Hwu W, Topalian S, Hwu P . Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366(26):2455-65. PMC: 3563263. DOI: 10.1056/NEJMoa1200694. View

Wen L, Zou X, Chen Y, Bai X, Liang T . Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression. Front Immunol. 2020; 11:2076. PMC: 7472830. DOI: 10.3389/fimmu.2020.02076. View

Zezza M, Kosinski C, Mekoguem C, Marino L, Chtioui H, Pitteloud N . Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports. BMC Endocr Disord. 2019; 19(1):144. PMC: 6929418. DOI: 10.1186/s12902-019-0467-z. View

Matsuura N, Koh G, Konishi C, Minamino S, Takahara Y, Harada H . Fulminant onset of insulin-dependent diabetes with positive anti-GAD antibody titers during treatment with nivolumab in a patient with NSCLC. Cancer Immunol Immunother. 2018; 67(9):1417-1424. PMC: 11028105. DOI: 10.1007/s00262-018-2203-3. View

Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R . Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer. JAMA Oncol. 2017; 4(3):374-378. PMC: 6583041. DOI: 10.1001/jamaoncol.2017.2925. View

Kapke J, Shaheen Z, Kilari D, Knudson P, Wong S . Immune Checkpoint Inhibitor-Associated Type 1 Diabetes Mellitus: Case Series, Review of the Literature, and Optimal Management. Case Rep Oncol. 2017; 10(3):897-909. PMC: 5731100. DOI: 10.1159/000480634. View

Godwin J, Jaggi S, Sirisena I, Sharda P, Rao A, Mehra R . Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer. J Immunother Cancer. 2017; 5:40. PMC: 5433051. DOI: 10.1186/s40425-017-0245-2. View

Baden M, Imagawa A, Abiru N, Awata T, Ikegami H, Uchigata Y . Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell death-1 therapy. Diabetol Int. 2019; 10(1):58-66. PMC: 6357237. DOI: 10.1007/s13340-018-0362-2. View

Li W, Wang H, Chen B, Zhao S, Zhang X, Jia K . Anti PD-1 monoclonal antibody induced autoimmune diabetes mellitus: a case report and brief review. Transl Lung Cancer Res. 2020; 9(2):379-388. PMC: 7225154. DOI: 10.21037/tlcr.2020.03.05. View

10.

Tsang V, McGrath R, Clifton-Bligh R, Scolyer R, Jakrot V, Guminski A . Checkpoint Inhibitor-Associated Autoimmune Diabetes Is Distinct From Type 1 Diabetes. J Clin Endocrinol Metab. 2019; 104(11):5499-5506. DOI: 10.1210/jc.2019-00423. View

11.

Stamatouli A, Quandt Z, Perdigoto A, Clark P, Kluger H, Weiss S . Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors. Diabetes. 2018; 67(8):1471-1480. PMC: 6054443. DOI: 10.2337/dbi18-0002. View

12.

Araujo M, Ligeiro D, Costa L, Marques F, Trindade H, Correia J . A case of fulminant Type 1 diabetes following anti-PD1 immunotherapy in a genetically susceptible patient. Immunotherapy. 2017; 9(7):531-535. DOI: 10.2217/imt-2017-0020. View

13.

Ribas A . Tumor immunotherapy directed at PD-1. N Engl J Med. 2012; 366(26):2517-9. DOI: 10.1056/NEJMe1205943. View

14.

Quandt Z, Young A, Anderson M . Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes. Clin Exp Immunol. 2020; 200(2):131-140. PMC: 7160652. DOI: 10.1111/cei.13424. View

15.

Yamamoto N, Tsurutani Y, Katsuragawa S, Kubo H, Sunouchi T, Hirose R . A Patient with Nivolumab-related Fulminant Type 1 Diabetes Mellitus whose Serum C-peptide Level Was Preserved at the Initial Detection of Hyperglycemia. Intern Med. 2019; 58(19):2825-2830. PMC: 6815891. DOI: 10.2169/internalmedicine.2780-19. View

16.

Miyoshi Y, Ogawa O, Oyama Y . Nivolumab, an Anti-Programmed Cell Death-1 Antibody, Induces Fulminant Type 1 Diabetes. Tohoku J Exp Med. 2016; 239(2):155-8. DOI: 10.1620/tjem.239.155. View

17.

Teramoto Y, Nakamura Y, Asami Y, Imamura T, Takahira S, Nemoto M . Case of type 1 diabetes associated with less-dose nivolumab therapy in a melanoma patient. J Dermatol. 2016; 44(5):605-606. DOI: 10.1111/1346-8138.13486. View

18.

Telo G, Carvalhal G, Cauduro C, Webber V, Barrios C, Fay A . Fulminant type 1 diabetes caused by dual immune checkpoint blockade in metastatic renal cell carcinoma. Ann Oncol. 2017; 28(1):191-192. DOI: 10.1093/annonc/mdw447. View

19.

Li L, Masood A, Bari S, Yavuz S, Grosbach A . Autoimmune Diabetes and Thyroiditis Complicating Treatment with Nivolumab. Case Rep Oncol. 2017; 10(1):230-234. PMC: 5465653. DOI: 10.1159/000456540. View

20.

Hong A, Yoon J, Kim H, Kang H . Immune Checkpoint Inhibitor-Induced Diabetic Ketoacidosis: A Report of Four Cases and Literature Review. Front Endocrinol (Lausanne). 2020; 11:14. PMC: 6997462. DOI: 10.3389/fendo.2020.00014. View